News - Cipla, Patents

Filter

Current filters:

CiplaPatents

Popular Filters

Report: Indian pharma companies’ innovation is increasing but fails to match Europe

10-01-2014

Innovation by Indian pharmaceutical companies has increased over the last few years but has not demonstrated…

CiplaDr Reddy's LaboratoriesIndiaPatentsPharmaceuticalResearch

Indian IPAB provides relief for Pfizer in Sutent patent revocation case

05-06-2013

India's Intellectual Property Appellate Board (IPAB) has provided global pharma behemoth Pfizer (NYSE:…

Asia-PacificCiplaPatentsPfizerPharmaceuticalSutent

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

Back to top